Please login to the form below

Not currently logged in
Email:
Password:

AD04

This page shows the latest AD04 news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer’s failure as Targacept trial disappoints

Another Alzheimer’s failure as Targacept trial disappoints

This June the UK's Medical Research Council (MRC) launched a £16m dementia research programme and Austrian biopharma company AFFiRiS claimed its drug candidate AD04 was the first therapy to show

Latest news

  • Burden of proof Burden of proof

    Breakthroughs in Alzheimer's are sorely needed, but there's still lots of work to do on AD04. ... So a wait-and-see approach remains prudent - only further, rigorous testing will tell if AD04 really is a breakthrough.

  • AFFiRiS claims a first in Alzheimer's disease therapy AFFiRiS claims a first in Alzheimer's disease therapy

    AD04 a peptide-based vaccine targeting beta amyloid, the material that makes up the characteristic amyloid plaques found in the brains of Alzheimer's patients. ... AD02 will now take a back seat while the company places more emphasis on AD04's development

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics